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Background: We assessed GGT fractions correlates and their reference values in the Offspring Cohort of the
Framingham Heart Study.
Methods: Correlates of GGT fractions were assessed by multivariable regression analysis in 3203 individuals
[47% men, mean age (SD): 59 (10) years]. GGT fractions reference values were established by empirical
quantile analysis in a reference group of 432 healthy subjects [45% men, 57 (10) years].
Results: Fractional GGT levels were higher in men than in women (Pb0.0001). In both sexes, fractions were
associated with: triglycerides were associated with b-GGT, alcohol consumption with m-, s- and f-GGT.
C-reactive protein with m- and s-GGT, while plasminogen activator inhibitor-1 with b- and f-GGT. Body
mass index, blood pressure, glucose and triglycerides correlated with b- and f-GGT. In comparison with the
reference group [b-GGT/s-GGT median (Q1–Q3): 0.51 (0.35–0.79)U/L], subjects affected by cardiovascular
disease or diabetes showed no change of b/s ratio [0.52 (0.34–0.79)U/L, 0.57 (0.40–0.83)U/L, respectively].
The b/s ratio was higher in presence of metabolic syndrome [0.61 (0.42–0.87)U/L, Pb0.0001], while lower
in heavy alcohol consumers [0.41 (0.28–0.64)U/L, Pb0.0001].
Conclusions: Metabolic and cardiovascular risk markers are important correlates of GGT fractions, in particu-
lar of b-GGT.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Total serum gamma-glutamyltransferase (GGT) activity is cur-
rently considered a sensitive but non-speciﬁc diagnostic marker of
hepato-biliary disorders and of alcohol abuse [1].
Serum GGT activity is affected by genetic factors, with heritability
estimated between 0.3 and 0.5 [2,3] but it has many other correlates
within its normal range. GGT shows a positive association with alco-
hol consumption and smoking habit, heart rate (HR), systolic (SBP)
and diastolic (DBP) blood pressure, obesity indexes, such as waist
circumference and body mass index (BMI), and with serum level of
glucose, triglycerides, total and LDL cholesterol and uric acid [1].
Also preexisting ischemic heart disease, diabetes mellitus, menopause
and use of antihypertensive medication, lipid lowering drugs and oral
contraceptives show a positive association with GGT level, while an
inverse association has been observed with coffee consumption,
physical activity, and lung function (FEV1) [1].
Several large epidemiological studies conducted in unselected
populations have demonstrated that serum GGT elevation is, an inde-
pendent predictor of all-cause mortality [4], andmortality due to either
hepatic or neoplastic diseases [5]. Circulating total GGT activity has been
also associated with an increased risk for arterial hypertension, diabe-
tes, and metabolic syndrome [6–8]. Serum GGT levels within the
upper normal range (25–40 U/L) were found to be associated with in-
creased risk of cardiovascular events, independently of established car-
diovascular risk factors, both in unselected populations (including the
community-based Framingham Heart Study) [8–12] and in patients
with prior coronary artery disease [13]. Accordingly, elevation of
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serum GGT concentrations was associated with an increase in the
SCORE risk function [14], and GGT was also found to incrementally
add to Framingham Risk Score function [15].
Recently, our group has set up a reproducible chromatographic
method [16], disclosing that total plasma GGT activity corresponds, in
healthy subjects, to four distinct fractions showing distinct physico-
chemical properties [17,18]. These fractions consist in three GGT-
containing molecular complexes b-, m-, s-, with molecular weight
>2000, 940, 140 kDa, respectively, and the free enzyme, f-GGT
(70 kDa). f-GGT is the most abundant fraction [19], while b-GGT corre-
lates with the level of serum triglycerides, LDL-cholesterol, C-reactive
protein (CRP), and DBP [20]. Interestingly, the active enzyme found in-
side the atherosclerotic plaque [21–23] was shown to correspond to the
b-GGT fraction [24].
While f-GGT is themajor circulating GGT fraction in healthy subjects
in both sexes, in the pathological conditions examined so far, b-GGT and
s-GGT accounted for most of total GGT increase [25,26]. Chronic viral
hepatitis C [25] and alcoholic-liver disease [26] are characterized by
the increase in s-GGT and the decrease in the b-GGT/s-GGT (b/s) ratio.
Conversely, non-alcoholic fatty liver disease (NAFLD) is associated
with the increase in both b-GGT and s-GGT fractions, without change
of the b/s ratio, in comparison with healthy controls [25].
The aims of the present investigation were to establish the refer-
ence values of GGT fractions, to assess their correlates in a large refer-
ence sample of healthy subjects from the Offspring Cohort of the
Framingham Heart Study, and to study the clinical correlates in the
larger community sample.
2. Materials and methods
2.1. Study participants
The Framingham Offspring Study began in 1971 with enrolment of
5124 offspring (and offspring spouses) of original cohort participants
[27]. Participants from the Framingham Offspring Study who attended
the sixth examination cycle (1995 to 1998), for which plasma-EDTA
samplewas available, were eligible for this investigation. The ﬁnal sam-
ple was 3203 individuals [1497 men, mean age (SD): 58.9 (9.9) years;
1706 women, 58.5 (9.7) years].
At each Framingham Heart Study visit, attendees undergo a phys-
ical examination and a medical history (by a Heart Study physician),
anthropometric measures, and laboratory assessment of vascular
risk factors. All participants provided written informed consent, and
the Institutional Review Board of the Boston Medical Center approved
the study protocol.
2.2. Measurements and deﬁnitions
For the present investigations, hypertension was deﬁned as a sys-
tolic blood pressure of 140 mm Hg or higher, a diastolic blood
pressure of 90 mm Hg or higher, or the use of antihypertensive med-
ications [28] Participants who smoked cigarettes regularly during the
year preceding the Heart Study visit were considered “current”
smokers. Alcohol intake was assessed by averaging the self-reported
weekly consumption of alcoholic drinks; USA dietary guidelines rec-
ommend the consumption of less than 14 drinks/week for men and
7 drinks/week for women; one drink contains 0.6 US ﬂuid ounces of
alcohol (14 g of ethanol). Body mass index (BMI) was calculated as
the weight in kilograms divided by the square of the height in meters
(kg/m2); obesity was deﬁned as BMI ≥30 kg/m2. Pre-diabetes condi-
tion was deﬁned as fasting blood glucose levels greater or equal to
100 mg/dL and less than 126 mg/dL; diabetes was deﬁned as a fasting
blood glucose level of 126 mg/dL or greater, or the use of any hypo-
glycemic agent [29]. Metabolic syndrome was deﬁned using modiﬁed
National Cholesterol Education Program (NCEP) criteria, which re-
quired at least three of the following: (1) elevated serum triglycerides
≥150 mg/dL; (2) HDL cholesterol b40 mg/dL [men] or b50 mg/dL
[women]; (3) BP ≥130 mm Hg systolic, ≥85 mm Hg diastolic, or use
of antihypertensive therapy; (4) fasting blood glucose ≥100 mg/dL;
and (5) BMI ≥30 kg/m2 [8]. Dyslipidemia was deﬁned as total serum
cholesterol ≥240 mg/dL or HDL cholesterol b40 mg/dL (men) or
b50 mg/dL (women) or lipid lowering treatment. Cardiovascular dis-
ease (CVD) was deﬁned as the presence of coronary heart disease,
heart failure, cerebrovascular disease, and peripheral vascular disease.
Renal disease was deﬁned empirically as serum creatinine level
≥2 mg/dL.
Usual levels of physical activity were assessed by a questionnaire.
Subjects were asked howmany hours per day were spent engaging in
sleep, sedentary activity, and slight, moderate, and heavy physical ac-
tivity. Based on the answers to these questions a physical activity
index was estimated, expressing how many times per week intense
physical activity (enough to sweat) was performed [30].
2.3. Reference sample
A reference sample constituted by healthy subjects was obtained
according to the following inclusion criteria: no smoking, no heavy al-
cohol intake, absence of CVD, hypertension, diabetes, obesity, renal
diseases, metabolic syndrome and dyslipidemia. The ﬁnal reference
sample comprised 432 subjects (194 men and 238 women).
2.4. Laboratory analysis
Blood samples were obtained from fasting participants between
8 and 9 AM at the Heart Study visit. Analyses were performed using
standard clinical laboratory procedures with automated analyzers
available at the Framingham Heart Study. In particular, B-type natri-
uretic peptide (BNP) was measured using the Shionogi Assay, high
sensitivity C-reactive protein (CRP) was measured through high sen-
sitivity Dade Behring BN100 nephelometer, plasminogen activator in-
hibitor 1 (PAI-1) was determined by ELISA kit (Biopool International,
Ventura CA); LDL cholesterol was calculated using the Friedewald
formula.
2.5. Fractional GGT analysis
Archived plasma-EDTA (ethylenediaminetetraacetic acid) sam-
ples, frozen at −80 °C and thawed once, were used. Fractional GGT
analysis was performed as described previously [16,19; pat. pend.
WO2009/001290-A3, The University of Pisa] using an FPLC (fast pro-
tein liquid chromatography) system (AKTA puriﬁer, GE Healthcare
Europe, Milan, Italy) equipped with a gel-ﬁltration column (Superose
6 HR 10/300 GL, GE Healthcare Europe) and ﬂuorescence detector
(Jasco FP-2020, Jasco Europe, Lecco, Italy). GGT activity was measured
using gamma-glutamyl-7-amido-4-methylcoumarin (Nova Chimica,
Milan, Italy) as substrate (0.03 mmol/L, ﬁnal concentration) and
glycylglycine (5.4 mmol/L, ﬁnal concentration) as acceptor of the
transpeptidation reaction. The ﬂuorescence detector operating at
excitation/emission wavelengths of 380/440 nm detected the amino-
4-methylcoumarin signal; the intensity of the ﬂuorescence signal was
expressed in arbitrary ﬂuorescence units.
Under this reaction conditions, area under curve is proportional to
GGT activity. Total area, between 10 and 25 mL elution volume, and
fractional GGT area was calculated by a MatLab program (Version 7
MathWorks, Inc.) to resolve overlapping peaks; the curve ﬁtting
was conducted with a nonlinear least-squares minimization algo-
rithm using four exponentially modiﬁed Gaussian (EMG) curves.
The reaction was calibrated analyzing plasma samples with known
total GGT activity (standards). The slope of the calibration curve
was used to convert total and fractional GGT area to U/L [19]. The
sum of fractional GGT activity represents on average the 99% of total
GGT activity.
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A 4.5 mmol/L stock solution of gamma-glutamyl-7-amido-4-
methylcoumarin was prepared in ethanol 40% v/v containing 0.01 N
NaOH and stored at −20 °C. This solution was diluted 25-fold into
0.25 M Tris–HCl buffer pH 8.5 (25 °C) daily.
2.6. Statistical analysis
Total and fractional GGT values betweenmales and females, healthy
subjects and heavy alcohol consumers, or subjects with CVD, or with
metabolic syndromewere compared usingWilconxon–Mann–Whitney
test.
To perform correlation analysis, several variables (total and frac-
tional GGT values, triglyceride, CRP, ﬁbrinogen and PAI-1 levels)
were natural-logarithmically transformed.
Bivariate linear (Pearson) correlations were estimated between an-
thropometric data (age, BMI, waist circumference), lifestyle (alcohol
and coffee consumption, physical activity index), biological variables
(glucose, HDL and LDL cholesterol, triglycerides, CRP, ﬁbrinogen,
PAI-1, HCys, BNP, etc.) and fractional GGT activity.
Multiple linear regressions, with total and fractional GGT activities
as dependent variables, were performed to quantify the relations of
several factors (age, waist circumference, alcohol consumption, sys-
tolic blood pressure, HDL and LDL cholesterol, triglycerides, CRP, ﬁ-
brinogen PAI-1, HCys). Variables not signiﬁcantly associated with
GGT were removed from ﬁnal models. Results were presented as a
standardized regression coefﬁcient. Considering the high number of
hypothesis tests carried out, Pb0.01 has been chosen as signiﬁcance
threshold to reduce the type I error (i.e. false positive).
In the healthy sample, fractional GGT activity reference limits
were estimated by empirical quantile (quantiles 0.025, 0.50 and
0.975). Statistical analysis was performed with SAS analysis software
(SAS/STAT version 9.2).
3. Results
3.1. Distribution of fractional GGT in the offspring cohort
The sample considered in the present study was of 3203 partici-
pants to the VI cycle of examination of the offspring cohort. The sam-
ple comprised 1497 men [mean (SD); age 58.9 (9.9) years] and 1706
women [58.5 (9.7) years]. Clinical and biochemical characteristics of
the sample are presented in Table 1.
In both sexes, total plasma GGT, as well as all fractions and the b/s
ratio, showed a skewed distribution and f-GGT was the prominent
fraction. Total GGT activity was higher in men [median (Q1–Q3),
26.1 (19.6–38.4) vs. 18.8 (14.2–27.5), (Pb0.001)], as it was for all
four GGT fractions (Pb0.0001). The b/s ratio was lower in men
(Pb0.0001; Table 1).
3.2. Correlates of fractional GGT activity in men and women: linear cor-
relation analysis
To study the biological correlations of each GGT fraction, we ﬁrst
performed a bivariate linear correlation analysis with known corre-
lates of total GGT activity available for the sixth examination cycle
of the offspring cohort (Table 2). Results for total GGT are reported
in the Supplemental Data Table 1.
In both sexes, all plasma GGT fractions were associated with body
mass index (BMI), waist circumference (WC), alcohol consumption
(apart from b-GGT in women), heart rate, systolic and diastolic blood
pressure, blood glucose, total cholesterol, triglycerides, C-reactive pro-
tein (CRP), and with plasminogen activator inhibitor 1 (PAI-1). Among
these variables, triglycerides and PAI-1 levels showed the highest Pear-
son correlation coefﬁcients with all the fractions. Age was correlated
with b-, m- and f-GGT fractions in women and with the b/s ratio in
both genders. Coffee consumption showed an inverse correlation only
with b-GGT in women. Physical activity inversely correlated with
b-GGT, both in men and women, and with f-GGT in men. Alcohol con-
sumption was positively correlated with the fractions m-, s- and f-GGT
in both sexes, the magnitude of the correlation being stronger in men.
Comparing correlation coefﬁcients for each biological variables
among GGT fractions, emerged that b-GGT and f-GGT, in both gen-
ders, showed the highest correlation coefﬁcient with all the consid-
ered cardiovascular risk factors: high levels of waist circumference
(WC), diastolic blood pressure (DBP), blood glucose, triglycerides
and low levels of HDL cholesterol. Plasma b-GGT concentration
showed the highest degree of correlation also with markers of inﬂam-
mation (CRP and ﬁbrinogen), while PAI-1 showed the highest corre-
lation coefﬁcients with f-GGT in both genders.
Compared to the individual fractions, the b/s ratio showed higher
correlation with WC, ﬁbrinogen and LDL cholesterol.
3.3. Clinical correlates of fractional GGT activity in men and women
Variables associated with total and GGT fractions were reported
separately for men and women in Table 3. Results for total GGT are
reported in the Supplemental Data Table 2.
Table 1
Characteristics of the offspring cohort (examination 6).
Men (1497) Women (1706)
Age, years 59 (10) 59 (10)
BMI, kg/m2 28.5 (4.3) 27.3 (5.7)
Waist circumference, cm 101 (11) 94 (15)
Smoking, n (%) 215 (14) 271 (16)
Alcohol consumption, drinks/week 7.3 (9.5) 3.2 (5.2)
Coffee consumption, cups/day 2.3 (2.4) 1.7 (1.8)
Physical activity index, times/week 2.7 (2.5) 2.1 (2.1)
Heart rate, bpm 62 (11) 65 (10)
SBP, mm Hg 130 (17) 127 (20)
DBP, mm Hg 77 (9) 74 (9)
Hypertension, n (%) 673 (45) 647 (38)
Obesity, n (%) 458 (31) 429 (25)
Pre-diabetes, n (%) 640 (43) 436 (26)
Diabetes mellitus, n (%) 184 (12) 137 (8)
Metabolic syndrome, n (%) 659 (44) 623 (37)
Renal diseases, n (%) 16.0 (1.1) 5.0 (0.3)
Cardiovascular diseases, n (%) 232 (15) 127 (7)
Coronary heart disease 177 (12) 77 (5)
Heart failure 43 (3) 31 (2)
Cerebrovascular disease 52 (3) 37 (2)
Peripheral vascular disease 22 (1.5) 13 (0.8)
Glucose, mg/dL 100 (94–110) 94 (88–102)
Creatinine, mg/dL 1.2 (1.1–1.3) 1.1 (1.0–1.2)
UARC, mg/g 4.8 (2.1–11.0) 8.5 (3.5–17.7)
Total cholesterol, mg/dL 197 (175–122) 209 (185–236)
HDL cholesterol, mg/dL 42 (35–50) 56 (46–67)
LDL cholesterol, mg/dL 126 (104–148) 125 (104–148)
Triglycerides, mg/dL 122 (85–175) 112 (78–165)
CRP, mg/dL 1.8 (0.9–3.8) 2.3 (1.0–5.7)
Fibrinongen, mg/dL 325 (288–376) 334 (294–381)
PAI-1, ng/mL 25.6 (16.9–36.1) 20.2 (12.2–31.8)
HCys, μmol/L 9.9 (8.4–12.0) 8.4 (7.0–10.3)
BNP, ng/L 6.7 (4.0–16.8) 10.0 (4.1–20.2)
Aldosterone, ng/dL 9.0 (7.0–13.0) 11.0 (7.0–15.0)
Renin, mUI/L 14.0 (8.0–24.5) 11.0 (6.0–19.0)
Aldosterone/renin 0.7 (0.4–1.2) 1.0 (0.6–1.7)
D-dimer μg/mL 299 (184–472) 335 (230–483)
Total GGT, U/L 26.1 (19.6–38.4) 18.8 (14.2–27.5)‡
b-GGT, U/L 3.8 (2.3–6.7) 2.7 (1.7–4.9)‡
m-GGT, U/L 0.6 (0.3–1.1) 0.3 (0.2–0.7)‡
s-GGT, U/L 7.9 (4.7–13.8) 4.9 (3.0–9.3)‡
f-GGT, U/L 13.4 (11.0–16.6) 10.1 (8.2–12.7)‡
b/s ratio 0.47 (0.33–0.68) 0.53 (0.36–0.80)‡
Data are presented as mean (SD) or median (Q1–Q3), unless otherwise indicated. BMI:
body mass index; BNP: brain natriuretic peptide; CRP: C-reactive protein; DBP: diastol-
ic blood pressure; HCys: homocysteine; PAI-1: plasminogen activator inhibitor 1; Q:
quartile; SBP: systolic blood pressure; UACR: urine-albumin to creatinine ratio.
Wilconxon–Mann–Whitney test, ‡Pb0.0001.
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Table 2
Linear correlation analysis, by sex, between biological variables and fractional GGT activity.
Men Women
Variables b-GGT m-GGT s-GGT f-GGT b/s ratio b-GGT m-GGT s-GGT f-GGT b/s ratio
Age −0.01 −0.06 −0.06 −0.06 0.09† 0.17‡ 0.07§ 0.04 0.12‡ 0.19‡
BMI 0.17‡ 0.15‡ 0.09† 0.18‡ 0.11‡ 0.27‡ 0.14‡ 0.12‡ 0.25‡ 0.21‡
Waist circumference 0.20‡ 0.15‡ 0.10‡ 0.20‡ 0.14‡ 0.32‡ 0.17‡ 0.15‡ 0.30‡ 0.24‡
Alcohol 0.15‡ 0.21‡ 0.28‡ 0.24‡ −0.24‡ 0.03 0.08§ 0.13‡ 0.09† −0.16‡
Coffee −0.06 −0.00 −0.04 0.01 −0.03 −0.07§ −0.01 −0.04 0.03 −0.05
Physical activity −0.08§ −0.03 −0.05 −0.06 −0.04 −0.06§ −0.04 −0.04 −0.02 −0.03
Heart rate 0.20‡ 0.18‡ 0.16‡ 0.17‡ 0.05 0.22‡ 0.14‡ 0.13‡ 0.21‡ 0.11‡
SBP 0.07§ 0.09† 0.07§ 0.09† −0.01 0.19‡ 0.10‡ 0.10‡ 0.19‡ 0.12‡
DBP 0.13‡ 0.14‡ 0.11‡ 0.15‡ 0.01 0.14‡ 0.06 0.07§ 0.15‡ 0.07†
Creatinine# −0.12‡ −0.08 −0.07† −0.12‡ −0.07 −0.08† −0.06 −0.06 −0.6 −0.03
Blood glucose 0.15‡ 0.09† 0.08§ 0.17‡ 0.09† 0.27‡ 0.17‡ 0.15‡ 0.31‡ 0.15‡
Total cholesterol 0.26‡ 0.27‡ 0.16‡ 0.30‡ 0.14‡ 0.30‡ 0.24‡ 0.13‡ 0.19‡ 0.23‡
HDL cholesterol −0.10† −0.05 0.11‡ −0.03 −0.34‡ −0.22‡ −0.13‡ −0.01 −0.21‡ −0.30‡
LDL cholesterol 0.07§ 0.15‡ −0.01 0.04 0.13‡ 0.25‡ 0.24‡ 0.07§ 0.18‡ 0.25‡
Triglycerides# 0.40‡ 0.26‡ 0.18‡ 0.32‡ 0.33‡ 0.45‡ 0.20‡ 0.19‡ 0.29‡ 0.36‡
CRP# 0.20‡ 0.20‡ 0.13‡ 0.17‡ 0.10‡ 0.30‡ 0.24‡ 0.19‡ 0.20‡ 0.14‡
Fibrinogen# 0.06 0.04 −0.05 −0.02 0.18‡ 0.16‡ 0.11‡ 0.01 0.09† 0.22‡
PAI-1# 0.40‡ 0.30‡ 0.26‡ 0.41‡ 0.19‡ 0.45‡ 0.29‡ 0.25‡ 0.53‡ 0.27‡
HCys# −0.01 0.07§ 0.01 0.02 −0.03 0.07§ 0.07§ 0.07§ 0.13‡ 0.00
UACR,# 0.04 0.04 0.01 0.04 0.03 0.03 0.04 0.04 0.09† −0.00
BNP# −0.08§ 0.05 −0.04 −0.12‡ −0.07§ −0.08§ −0.05 −0.03 −0.07§ −0.07§
Aldosterone# 0.08§ 0.06 0.06 0.11‡ 0.03 0.09† 0.09† 0.08† 0.10‡ 0.01
Renin# 0.06 0.06 0.04 0.04 0.04 0.08† 0.07§ 0.07§ 0.14‡ 0.01
Aldosterone/Renin# −0.01 −0.01 −0.01 0.02 −0.00 −0.03 −0.02 −0.02 −0.08† −0.01
D-dimer# −0.02 −0.01 −0.06 −0.06§ 0.07§ 0.12‡ 0.08§ 0.04 0.07§ 0.12‡
Data are Pearson correlation coefﬁcients. BMI: body mass index; BNP: brain natriuretic peptide; CRP: C-reactive protein; DBP: diastolic blood pressure; HCys: homocysteine; PAI-1:
plasminogen activator inhibitor 1; SBP: systolic blood pressure; UACR: urine-albumin to creatinine ratio. #Linear correlation analysis have been performed on ln-transformed data,
also fractional GGT data were ln-transformed. Statistical signiﬁcance level: §Pb0.01; †Pb0.001; ‡Pb0.0001, otherwise P≥0.01.
Table 3
Clinical correlates of fractional GGT, by sex, as determined by multivariable linear regression analysis.
b-GGT m-GGT s-GGT f-GGT b/s ratio
Variable Std.
estimate
95% CI Std.
estimate
95% CI Std.
estimate
95% CI Std.
estimate
95% CI Std.
estimate
95% CI
Men (n=1422)
Age −0.03 −0.08 0.01 −0.08† −0.13 −0.03 −0.06 −0.11 −0.01 −0.06 −0.10 −0.01 0.09† 0.04 0.15
Waist circumference 0.03 −0.02 0.09
Alcohol 0.07§ 0.03 0.12 0.16‡ 0.12 0.21 0.18‡ 0.13 0.23 0.19‡ 0.14 0.23 −0.18‡ −0.23 −0.13
Heart rate 0.08§ 0.03 0.12 0.08† 0.03 0.13 0.08† 0.03 0.13 0.06§ 0.02 0.11
SBP −0.06 −0.11 −0.01
Blood glucose 0.03 −0.02 0.08 0.02 −0.03 0.07 0.02 −0.02 0.07 0.07§ 0.02 0.12
HDL cholesterol 0.12‡ 0.07 0.18 0.20‡ 0.14 0.26 −0.15‡ −0.21 −0.09
LDL cholesterol 0.05 0.01 0.10 0.14‡ 0.09 0.19 0.05 −0.00 0.09 0.15‡ 0.11 0.20
Triglycerides# 0.35‡ 0.29 0.41 0.15‡ 0.10 0.20 0.18‡ 0.12 0.24 0.19‡ 0.14 0.24 0.24‡ 0.19 0.30
CRP# 0.11‡ 0.06 0.15 0.18‡ 0.12 0.24 0.16‡ 0.10 0.22 0.15‡ 0.09 0.20 −0.06 −0.12 0.00
Fibrinogen,# −0.08† −0.14 −0.02 −0.12‡ −0.18 −0.06 −0.14‡ −0.20 −0.08 0.12‡ 0.06 0.18
PAI-1# 0.23‡ 0.17 0.28 0.16‡ 0.10 0.21 0.17‡ 0.11 0.22 0.25‡ 0.20 0.30 0.06 0.00 0.12
HCys# 0.04 −0.00 0.09 0.00 −0.05 0.05 0.01 −0.04 0.06 −0.05 −0.10 −0.00
Women (n=1616)
Age 0.02 −0.02 0.07 −0.02 −0.07 0.03 −0.04 −0.09 0.01 −0.01 −0.06 0.03 0.11‡ 0.06 0.16
Waist circumference 0.07 0.01 0.13
Alcohol 0.05 0.01 0.095 0.08† 0.04 0.13 0.09† 0.04 0.13 0.07† 0.03 0.12 −0.06† −0.11 −0.02
Heart rate 0.04 −0.00 0.08 0.02 −0.03 0.06 0.03 −0.02 0.07 0.05 0.01 0.09
SBP −0.03 −0.08 0.02
Blood glucose 0.04 −0.00 0.09 0.07§ 0.02 0.12 0.05 −0.00 0.10 0.11‡ 0.06 0.16
HDL cholesterol 0.04 −0.01 0.09 0.11† 0.06 0.17 −0.11‡ −0.16 −0.05
LDL cholesterol 0.12‡ 0.08 0.17 0.20‡ 0.16 0.25 0.09† 0.04 0.13 0.14‡ 0.10 0.19
Triglycerides# 0.28‡ 0.23 0.33 0.04 −0.01 0.09 0.14‡ 0.08 0.20 0.07§ 0.03 0.12 0.20‡ 0.15 0.26
CRP# 0.08† 0.04 0.13 0.18‡ 0.12 0.23 0.14‡ 0.08 0.19 0.02 −0.03 0.07 −0.09§ −0.14 −0.03
Fibrinogen,# −0.06 −0.11 −0.00 −0.10† −0.15 −0.04 −0.08§ −0.12 −0.03 0.11‡ 0.06 0.16
PAI-1# 0.26‡ 0.21 0.31 0.16‡ 0.11 0.21 0.19‡ 0.13 0.25 0.42‡ 0.38 0.47 0.08§ 0.02 0.13
HCys# 0.02 −0.02 0.07 0.06 0.01 0.11 0.07§ 0.03 0.11 −0.09† −0.13 −0.04
Standardized regression coefﬁcients (95% CI) are shown. CRP: C-reactive protein; DBP: diastolic blood pressure; PAI-1: plasminogen activator inhibitor 1. #Linear regression anal-
ysis have been performed on ln-transformed data, also fractional GGT data were ln-transformed. Statistical signiﬁcance level: §Pb0.01; †Pb0.001; ‡Pb0.0001, otherwise P≥0.01.
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Multivariable linear regression analysis showed that, in both
sexes, the four fractions were mainly inﬂuenced by the same vari-
ables; triglycerides level was the main predictor of b-GGT, whereas
alcohol consumption was speciﬁcally associated with m-, s- and
f-GGT. CRP and PAI-1 levels also showed to be important correlates
of all GGT fractions.
Serum lipid levels showed different associations with the three high
molecularweight GGT fractions inmen andwomen: triglycerides levels
were associated with b-GGT and s-GGT in both sexes but with m-GGT
only in men; LDL-cholesterol was associated with b-GGT and m-GGT
both in men and women; while HDL-cholesterol was associated with
s-GGT in both sexes and with b-GGT only in men. LDL-cholesterol
showed higher standardized regression coefﬁcient values in women in
comparison with men; the opposite was true for HDL-cholesterol. Fi-
brinogen showed a negative association with m-, s- and f-GGT, both in
men and women, in particular s- and f-GGT inmen showed the highest
standardized regression coefﬁcients.
In both sexes, the main positive correlates of b/s ratio were LDL-
cholesterol, triglycerides levels and ﬁbrinogen while alcohol con-
sumption and HDL-cholesterol showed an inverse association.
3.4. Total fractional GGT activity in the healthy subjects: reference values
To estimate the reference values for fractional GGT activity, among
participants at the sixth examination cycle of the Offspring cohort, we
selected a Reference sample consisting of 432 healthy subjects (13.2%
of participants), 194 men [mean (SD), age 55.6 (9.8) years] and 238
women [age 57.6 (9.6) years]. We excluded all major medical condi-
tions potentially associated with alteration of circulating GGT activity,
as detailed in the Material and Methods section. The clinical and bio-
chemical characteristics of these subjects are presented in the Supple-
mental Data Table 3; UACR, BNP, aldosterone, renin, D-dimer and
homocysteine values were within normal range (data not shown).
Also in the reference sample, total plasma GGT values were higher
in men than in women (Pb0.0001), analogously all GGT fractions
(b-GGT, Pb0.05; m-GGT, Pb0.01; s- and f-GGT, Pb0.0001). Levels of
b/s ratio, instead, were lower in men than in women (Pb0.001; Sup-
plemental Data Table 2).
Lower (2.5th quintile), median (50th quintile) and upper (97.5th
quintile) reference limits are presented for total and each GGT frac-
tions separately for men and women in Table 4.
3.5. Total and fractional GGT activity in subsets
We compared total and fractional GGT activities in the reference
group of healthy subjects with corresponding levels in heavy alcohol
consumers or subjects affected by cardiovascular disease (CVD), met-
abolic syndrome, or diabetes (Table 5), according to the deﬁnitions
noted in Materials and methods section.
In both genders, all the aforementioned conditions were associat-
ed with a mild, but statistically signiﬁcant, increase of total and frac-
tional GGT values, except for s-GGT in cardio vascular disease (CVD)
subset and b-GGT in women CVD-subset. Alcohol consumption was
associated with the prevalent elevation of s-GGT (men: 2.0 fold;
women: 1.8 fold) over the other fractions, thus the b/s ratio resulted
signiﬁcantly lower than in healthy subjects (men: Pb0.001; women:
Pb0.0001). In both genders, subjects affect by CVD or diabetes expe-
rienced a proportional elevation of GGT fractions, in fact the b/s ratio
did not change in comparison with healthy subjects. The latter,
instead, was increased in presence of metabolic syndrome (men:
Pb0.001; women: Pb0.01).
4. Discussion
The analysis of Framingham Offspring cohort shows that the cor-
relates of plasma activity vary for each GGT fraction: the b-GGT frac-
tion is mostly associated with serum triglyceride levels in both sexes,
while m- and s-GGT are mostly correlated with either alcohol con-
sumption and HDL or LDL cholesterol level. Prominent correlates of
f-GGT in both sexes were PAI-1 level and triglyceride level and alco-
hol consumption in men, and blood glucose in women.
We also established the reference values for each of the four GGT
fractions in a subgroup of healthy subjects (n=432), values that cor-
respond to median values previously reported in 200 blood donors
[19]. Fractional GGT analysis showed signiﬁcant differences in activity
of all fractions between men and women.
Analysis of the clinical correlates in the whole community sample
conﬁrmed the results of bivariate correlations. Plasma total GGT ac-
tivity is positively associated with already described factors such as
alcohol consumption, triglycerides, LDL cholesterol, blood pressure,
body mass index, waist circumference, serum glucose, ﬁbrinogen
and CRP [1], and negatively with HDL cholesterol, physical activity.
The multivariable analysis showed that alcohol consumption, triglyc-
erides, HDL and LDL cholesterol and CRP were the only independent
correlates, together with PAI-1 hereby described for the ﬁrst time.
As expected, bivariate correlations and multivariable linear re-
gression analyses conducted separately for each GGT fraction showed
that biological and clinical correlations described for total GGT actual-
ly depended on the diverse association of the above mentioned fac-
tors with speciﬁc fractions.
Alcohol consumption showed a prominent association with the
m- and s-GGT fractions: in fact, we have previously reported that
fractional GGT proﬁle of alcohol addicts is characterized by a greatest
increase in m- and s-GGT levels vs. other fractions [26]. We have also
previously observed the elevation of s-GGT fraction in patients with
chronic hepatitis C, this suggesting the s-GGT as a marker of hepato-
cellular damage. The negative correlation found between s-GGT and
plasma ﬁbrinogen in the Framingham cohort might correspond to un-
derlying liver dysfunction.
Markers of metabolic syndrome (BMI, DBP, glucose, triglycerides)
showed the highest positive correlation with the b- and f-GGT frac-
tions. These results conﬁrm and support the recent ﬁnding that
b-GGT fraction holds the best speciﬁcity and sensitivity for the diag-
nosis of NAFLD [25]. b- and f-GGT showed a negative correlation
with physical activity as it had been previously showed for total
GGT activity. It is well known that regular exercise improves many
cardiovascular and metabolic risks factors, including the intrahepatic
triglyceride content [31].
The existence of a correlation between PAI-1 and total GGT levels
has been previously reported only in small selected cohorts of
hypertriglyceridemic and insulin-resistant patients [32,33]; in the
present investigation we observed that plasma PAI-1 is among the
strongest independent predictors of especially b-GGT and f-GGT. En-
hanced expression of both PAI-1 and GGT has been shown in a variety
of liver injury models, including bile duct ligation and alcohol-
induced liver injury [34,35], affecting hepatic protein synthesis.
Furthermore, plasma PAI-1 levels were strongly correlated with the
cluster of variables deﬁning the metabolic syndrome (i.e.: insulin-
resistance, obesity, glucose and lipid metabolic imbalance) [36].
Table 4
Fractional GGT reference limits (U/L).
Men (n=194) Women (n=238)
2.5th 50th 97.5th 2.5th 50th 97.5th
Total GGT 11.4 23.1 108.8 8.8 16.8 87.3
b-GGT 0.8 3.1 18.1 0.8 2.5 30.1
m-GGT 0.01 0.48 4.19 0.01 0.29 3.51
s-GGT 2.0 6.3 71.6 1.4 4.1 46.4
f-GGT 6.9 11.7 24.2 5.6 9.4 20.9
b/s ratio 0.16 0.46 1.25 0.18 0.59 1.61
Data are from empirical quantile estimation.
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Comparison of total GGT values between the subsets of healthy
subjects and of subjects affected by CVD, metabolic syndrome, diabe-
tes, or characterized by heavy alcohol consumption conﬁrmed that
total plasma GGT activity is a sensitive but nonspeciﬁc marker. On
the other hand, each subset was characterized by a speciﬁc fractional
GGT pattern, better described by the b/s ratio. Based to our correlation
analysis, heavy alcohol intake was characterized by the highest values
of s-GGT and the lowest b/s ratio, while individuals with metabolic syn-
drome and diabetes had the highest values of both b-GGT and b/s ratio.
As a perspective, the estimation of b/s ratio could improve the interpre-
tation of total GGT elevation, as already observed in small selected co-
horts of patients affected by liver steatosis or chronic viral hepatitis C,
where an increase has been associated with a metabolic liver dysfunc-
tion or a decrease with hepatocellular damage [25].
In conclusion, the present study indicates that known cardiovas-
cular and metabolic risk markers are important correlates of GGT
fractions, in particular of b-GGT. The study of GGT fractions could per-
mit a better understanding of the pathogenesis of diseases associated
with GGT increase, thus allowing a better clinical use of the GGT test.
Prospective studies are needed to establish the risk for metabolic dis-
ease and cardiovascular events associated with each GGT fractions.
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